- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05916326
Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula Polymorpha)
A Phase III Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula Polymorpha) in Healthy People Aged 6 Months to 13 Years
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Yun Kang
- Phone Number: (+86)13911277806
- Email: kangyun@sinopharm.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged from 6 months to 13 years old, and can provide legal identity certificate;
- Volunteers and/or their guardians have the ability to understand the study requirements and process, agree to participate in the clinical trial and sign the informed consent, and can participate in all planned follow-up visits ( by an authorized entrusted person on the premise of written authorization by the guardian the informed consent can be signed);
- Those <12 months old: born in full-term pregnancy (gestational week 37-42 weeks) and birth weight ≥ 2.5kg.
Exclusion Criteria:
First dose exclusion criteria:
- Axillary body temperature > 37.0°C ;
- Have a history of chronic gastrointestinal diseases;
- Had gastroenteritis requiring treatment or current diarrhea, vomiting or other digestive system diseases within 7 days;
- Have a history of allergy to any excipients of the experimental vaccine (L-histidine, sodium chloride, aluminum hydroxide and water for injection, etc.);
- Have a history of severe allergy to any vaccine or drug, such as anaphylactic shock, allergic laryngeal edema, allergic purpura, Arthus reaction;
- Have been diagnosed with congenital or acquired immunodeficiency, or received immunosuppressant treatment, such as the application of systemic glucocorticoid therapy for more than 2 consecutive weeks 2 months before vaccination, such as prednisone or similar drugs > 5mg/day (note: use of topical and inhaled/nebulized steroids can participate);
- Infectious diseases, such as: tuberculosis, viral hepatitis or parents infected with human immunodeficiency virus HIV;
- Thrombocytopenia, any coagulation disorders, or intramuscular injection contraindications receiving anticoagulant therapy etc.;
- The volunteer himself or his biological parents have a history of convulsions (except for febrile convulsions in children), epilepsy and mental illness;
- Serious diseases or congenital malformations that may interfere with the conduct or completion of the research (including but not limited to: asthma and other respiratory diseases or during the attack of chronic bronchitis, Down syndrome, thalassemia, heart disease, encephalopathy, kidney disease, self immune diseases, genetic allergies, Guillain-Barre Syndrome, severe skin diseases, severe malnutrition, severe developmental disorders, etc.);
- Asplenia, functional asplenia, and asplenia or splenectomy caused by any reason;
- Have received blood or blood-related products or immune globulin within 3 months (hepatitis B immune globulin and rabies patient immune globulin are acceptable);
- vaccinated inactivated/recombinant vaccines (non-live vaccines) within 7 days, and inoculate live attenuated vaccines or COVID-19 vaccines within 14 days;
- Acute illness or acute exacerbation of chronic disease within 3 days;
- Have taken antipyretic, analgesic or antiallergic drugs within 3 days;
- Plan to move before the end of the study or leave the local area for a long time during the scheduled study visit;
- Participating in or planning to participate in another interventional research during the study process;
- The investigators believe that the volunteers have other conditions that may interfere with the evaluation of the research purpose;
- <12 months old: the baby is born with abnormal labor process (dystocia, instrumental midwifery) or has a history of suffocation, nervous system damage, current pathological jaundice, perianal abscess, severe eczema;
- If there have been serious adverse reactions after vaccination in the past, the investigator will determine whether the volunteer is enrolled or not according to the actual situation.
If items 1, 3, 13, 14, and 15 of the exclusion criteria are met, the volunteer's enrollment will be postponed.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: placebo group
|
Intramuscular injection of placebo in the deltoid muscle of the upper arm
|
Experimental: Experimental vaccine group
|
Intramuscular injection of Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant
(Hansenula polymorpha) in the deltoid muscle of the upper arm
|
Experimental: Experimental vaccine group(Immunogenic subgroup )
|
Intramuscular injection of Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant
(Hansenula polymorpha) in the deltoid muscle of the upper arm
|
Placebo Comparator: placebo group(Immunogenic subgroup)
|
Intramuscular injection of placebo in the deltoid muscle of the upper arm
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate efficacy of moderate/severe acute gastroenteritis caused by laboratory-confirmed (RT-PCR) infection with GI.1 or GII.4 norovirus after full vaccination with Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula polymorpha)
Time Frame: 14 days after the full course of vaccination to end of study(about two years)
|
Efficacy:The sum of the incidence rate of the placebo group and the incidence rate of the experimental group, divided by the incidence rate of the placebo group
|
14 days after the full course of vaccination to end of study(about two years)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the efficacy of against moderate/severe acute gastroenteritis caused by laboratory-confirmed (RT-PCR) infection with any strain of norovirus
Time Frame: 14 days after the full course of vaccination to end of study(about two years)
|
after full vaccination with Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula polymorpha) Efficacy:The sum of the incidence rate of the placebo group and the incidence rate of the experimental group, divided by the incidence rate of the placebo group |
14 days after the full course of vaccination to end of study(about two years)
|
To evaluate efficacy of any gastroenteritis caused by laboratory-confirmed (RT-PCR) infection with GI.1 or GII.4 norovirus after full vaccination with Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula polymorpha)
Time Frame: 14 days after the full course of vaccination to end of study(about two years)
|
Efficacy:The sum of the incidence rate of the placebo group and the incidence rate of the experimental group, divided by the incidence rate of the placebo group
|
14 days after the full course of vaccination to end of study(about two years)
|
To evaluate the efficacy of any gastroenteritis caused by laboratory-confirmed (RT-PCR) infection with any strain of norovirus after full vaccination with Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula polymorpha)
Time Frame: 14 days after the full course of vaccination to end of study(about two years)
|
Efficacy:The sum of the incidence rate of the placebo group and the incidence rate of the experimental group, divided by the incidence rate of the placebo group
|
14 days after the full course of vaccination to end of study(about two years)
|
IgG of NoV GI.1 and GII.4 after full vaccination with Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula polymorpha)
Time Frame: 14th day after the full course of vaccination
|
only Immunogenic subgroup
|
14th day after the full course of vaccination
|
HBGA-blocking antibody geometric mean titer (GMT) of NoV GI.1 and GII.4 after full vaccination with Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula polymorpha)
Time Frame: 14th day after the full course of vaccination
|
only Immunogenic subgroup
|
14th day after the full course of vaccination
|
Positive conversion rates of GMT for NoV GI.1 and GII.4 after full vaccination with Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula polymorpha)
Time Frame: 14th day after the full course of vaccination
|
only Immunogenic subgroup
|
14th day after the full course of vaccination
|
Compared to before vaccination,the growth multiple of GMT for NoV GI.1 and GII.4 antibodies after full vaccination with Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula polymorpha)
Time Frame: 14th day after the full course of vaccination
|
only Immunogenic subgroup
|
14th day after the full course of vaccination
|
HBGA-blocking antibodies Geometric mean titer (GMT) of NoV GI.1 and GII.4 after full vaccination with Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula polymorpha)
Time Frame: 180th,360th,540th,720th day after the full course of vaccination
|
only Immunogenic subgroup
|
180th,360th,540th,720th day after the full course of vaccination
|
IgG of NoV GI.1 and GII.4 after full vaccination with Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula polymorpha)
Time Frame: 180th,360th,540th,720th day after the full course of vaccination
|
only Immunogenic subgroup
|
180th,360th,540th,720th day after the full course of vaccination
|
the incidence and severity of adverse reactions/events within 30 minutes after each dose of vaccination
Time Frame: The period after each dose to 30 minutes after the dose
|
The period after each dose to 30 minutes after the dose
|
|
the incidence and severity of adverse reactions/events within 0-7 days after each dose of vaccination
Time Frame: The period after each dose to 7 days after the dose
|
The period after each dose to 7 days after the dose
|
|
the incidence and severity of non-solicited adverse reactions/events within 28 days after each dose of vaccination
Time Frame: The period after each dose to 28 days after the dose
|
The period after each dose to 28 days after the dose
|
|
the incidence of SAE from the first dose of vaccination to end of study
Time Frame: the first dose of vaccination to end of study(about two years)
|
the first dose of vaccination to end of study(about two years)
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CXSL1700011-III
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Norwalk Gastroenteritis
-
National Vaccine and Serum Institute, ChinaZhengzhou University; Lanzhou Institute of Biological Products Co., Ltd; Beijing...RecruitingNorwalk Gastroenteritis | Norovirus InfectionsChina
-
National Vaccine and Serum Institute, ChinaZhengzhou University; Lanzhou Institute of Biological Products Co., Ltd; Beijing...CompletedNorwalk Gastroenteritis | Norovirus InfectionsChina
-
TakedaCompleted
-
GlaxoSmithKlineCompletedRotavirus Gastroenteritis | Nosocomial Rotavirus Gastroenteritis
-
University Hospital for Infectious Diseases, CroatiaCompletedRotavirus GastroenteritisCroatia
-
National Institute of Allergy and Infectious Diseases...CompletedGastroenteritis NorovirusUnited States
-
Merck Sharp & Dohme LLCCompleted
-
MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd.ParexelCompletedRotavirus GastroenteritisBangladesh
-
PATHCenters for Disease Control and Prevention; Noguchi Memorial Institute for... and other collaboratorsCompletedRotavirus GastroenteritisGhana
-
GlaxoSmithKlineCompletedRotavirus GastroenteritisGreece
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States